Fintel reports that on January 16, 2025, Wolfe Research downgraded their outlook for Edwards Lifesciences (NYSE:EW) from Peer ...

Daniel J. Lippis, the Corporate Vice President for JAPAC at Edwards Lifesciences Corp (NYSE:EW), has disclosed recent stock ...

In 2024, the Hatch-Waxman Act continued to play a critical role in the U.S. pharmaceutical landscape, driving the dynamics between ...

Edwards Lifesciences (EW) stock faces a downgrade at Wolfe due to concerns over its TAVR market prospects. Read more here.

Wedgewood Partners, an investment management company, released its fourth-quarter 2024 investor letter. A copy of the letter ...

Wolfe Research downgraded Edwards Lifesciences (EW) to Underperform from Peer Perform with a $60 price target The firm says its core ...

Capital Investment Advisors LLC lowered its stake in shares of Edwards Lifesciences Co. (NYSE:EW – Free Report) by 2.4% during the fourth quarter, according to its most recent disclosure with the ...

This was the stock's fourth consecutive day of losses.

Sinclair joins VCCP from Grey Health and Wellness, where she served as president for just over four years. Creative agency ...

Cardiac device innovations made waves in 2024, with regulatory approvals, clinical breakthroughs, and product launches ...

In a report released yesterday, Lee Hambright from Bernstein maintained a Hold rating on Edwards Lifesciences (EW – Research Report). The ...

Edwards Lifesciences Corp (EW) stock saw a decline, ending the day at $71.09 which represents a decrease of $-2.33 or -3.17% from the prior close of $73.42. The stock opened at $70.54 and touched a ...